A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

As a dose-response relationship has been suggested for cisplatin, it appeared attractive to explore high-dose-intensity regimens in non-small-cell lung cancer. In a phase I study of weekly administration of cisplatin combined with oral etoposide we achieved a cisplatin dose intensity of 52.5-60 mg/m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 1997, Vol.40 (4), p.347-352
Hauptverfasser:	PLANTING, A, KHO, S, VAN DER BURG, M, GOEY, H, SCHELLENS, J, VAN DEN BENT, M, VAN DER GAAST, A, DE BOER-DENNERT, M, STOTER, G, VERWEIJ, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Cisplatin - administration & dosage Cisplatin - therapeutic use Dose-Response Relationship, Drug Etoposide - administration & dosage Etoposide - therapeutic use Female Humans Infusions, Intravenous Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical sciences Middle Aged Pharmacology. Drug treatments Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!